Introducing DCISionRT® – empowering women with breast cancer
Biological profiling for personalised treatment
What is DCISionRT®?
DCISionRT® is a new risk assessment test now available in Australia. The test looks at the likelihood of your ductal carcinoma in situ (DCIS) recurring after surgery, the risk of the disease spreading, and the impact of radiation therapy in reducing that risk.
DCISionRT assists you and your doctor to select treatment based on the biology of your tumour, in addition to the traditional clinical and pathology factors.
GenesisCare has partnered with PreludeDx to launch DCISionRT across our global network, with support from surgeons, pathology providers, and hospitals around the world.
DCISionRT looks at women diagnosed with DCIS and assesses their 10-year risk of recurrence or of developing invasive disease with or without radiation therapy. It is the only test developed specifically for this purpose.
The outcomes of the test show whether your risk is ‘low’ or ‘elevated’ and assesses the potential benefits of radiation therapy. Your test results are then used as a decision tool for you and your doctor when considering treatment options.
We test your DCIS with 7 biomarkers, their interactions and their relationship to 4 factors about you:
- Your age at diagnosis
- How the lesion was discovered (by mammography or physical exam)
- The extent of the lesion (size)
- Whether the rim of tissue surrounding the lesion was free of DCIS (margin)
The more information your doctor has about your individual biological make-up, the more personalised they can make your treatment, and this increases the likelihood of better outcomes. The additional biological information provided by DCISionRT can give you and your doctor insights into the risks you have of the disease recurring and your likelihood of benefiting from radiation therapy. A truly personalised approach.
Your doctor can arrange the DCISionRT test for you. The test can be applied to the breast tissue sample taken as part of your biopsy or breast surgery; no additional procedure is required.
The DCISionRT test has been validated in published studies with over 3,500 DCIS patients worldwide.1-4
At GenesisCare, we challenge ourselves every day to find new and better ways to treat illness and disease and deliver better outcomes for our patients.
As part of GenesisCare’s commitment to optimal patient care, each DCIS patient undergoing the DCISionRT test will be asked for permission for their data to go into a registry. This registry will provide prospective data, used to improve patient care and treatment outcomes. Your doctor will discuss this with you at your appointment.
Click here for further information.
What is Ductal Carcinoma in Situ (DCIS)?
DCIS is the presence of abnormal cells inside a milk duct in one or both breasts. DCIS is considered the earliest form of breast cancer and is sometimes referred to as Stage 0 (zero). DCIS is non-invasive, meaning it has not spread out from the milk duct, and has a lower risk of progressing to invasive breast cancer.
DCIS itself is not considered life threatening, however, a recent study suggested that women with DCIS have a 3-fold increased risk of death of breast cancer compared with women without DCIS because of the variations in treatment practice, due to geographical access and clinic protocols.5,6
Click here for more information about breast cancer and treatment.
Get in touch
- Weinmann S, et al. Clin Cancer Res 2020; (26)(15):4054 – 4063.
- Bremer TM, et al. Clin Cancer Res 2018; 1;24(23):5895 – 5901.
- Warnberg F, et al. Cancer Res 2018; 78 (4 Suppl);GS5 – 08.
- PreludeDX 2016-2017. Data on file.
- Australian Government, Australian Institute of Health and Welfare 2020. Available here. [Accessed on: 18/01/21]
- van Seijen M, et al. Br J Cancer 2019; 13;121(4):285 – 292.